Trimetrexate Pregnancy and Breastfeeding Warnings
Trimetrexate is also known as: Neutrexin
Trimetrexate Pregnancy Warnings
Trimetrexate has been assigned to pregnancy category D by the FDA. Trimetrexate has been shown to be teratogenic in animals at doses 1/20 to 1/2 of normal human doses. Fetal toxicities include skeletal, cardiovascular, ocular, and visceral abnormalities. The use of trimetrexate is considered to be contraindicated during pregnancy.
Trimetrexate Breastfeeding Warnings
There are no data on the excretion of trimetrexate into human milk. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, breast-feeding should be discontinued if the mother is treated with trimetrexate.
References for pregnancy information
- Product Information. NeuTrexin (trimetrexate). Apothecon Inc. 2022.
References for breastfeeding information
- Product Information. NeuTrexin (trimetrexate). Apothecon Inc. 2022.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.